A sort of blood purification therapy called CRRT is applied to individuals who have AKI. The blood of the patient is passed through a specific filter during this therapy in order to eliminate fluid and uremic toxins and deliver clean blood to the body. Patients who are hemodynamically unstable—characterized by fluctuating blood pressure and heart rates—can better tolerate this therapy because of its gradual and continuous nature, which is normally carried out over a 24-hour period.
Medical products which are necessary to perform CRRT on the patient include:
In addition, the COVID-19 pandemic has caused a sharp increase in demand for CRRT globally. As a result, there are now more financial incentives and regulatory support from various government bodies for the market for continuous renal replacement treatment.
The need for continuous renal replacement treatment is therefore anticipated to rise in response to the rising incidence of AKI and AKF globally. The International Society of Nephrology (INR) estimates that 13.3 million new cases of AKI are reported each year around the globe. It is predicted that this would hasten the implementation of continuous renal replacement treatment. The prevalence of kidney-related disorders is anticipated to rise dramatically due to the worldwide geriatric population's rapid expansion. As a result, the market for continuous renal replacement treatment is anticipated to develop significantly over the course of the projected period.
People in emerging economies value affordability, thus they favor lower-cost goods. Although though continuous renal replacement treatment in underdeveloped nations is expensive, a huge percentage of the population cannot afford these operations due to their poor purchasing power. As a result, both in developing and industrialized nations, demand for and adoption of continuous renal replacement treatment are constrained.
Players in the continuous renal replacement treatment market should find considerable development possibilities in emerging economies like China, India, Brazil, and Mexico. Players are increasingly concentrating on conducting strategic initiatives to enhance their presence in these areas and access a large number of clients in order to take advantage of the huge growth potential in emerging nations. Due to less strict data requirements, regulatory rules in the Asia-Pacific area are also more flexible and business-friendly.
Continuous renal replacement treatment requires complicated nursing care and is a highly specialized, important therapy. For the continual assessment of indications, maintaining appropriate vascular access, minimizing unneeded interruptions, and reducing problems in patients receiving continuous renal replacement treatment, it is essential that ICU nurses have the requisite training. Unfortunately, there are currently not enough registered nurses working in ICU situations. Also, the difficulty of continuous renal replacement treatment is probably going to restrain market expansion.
The global market for continuous renal replacement treatment is anticipated to be worth $1.38 billion in 2023 and to reach $2.25 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.3% from 2023 to 2030. The market is expected to grow as a result of a number of factors, including the rising prevalence of AKI globally, the rise in the number of ICU patients with AKI, the rise in sepsis cases, and the growing clinical benefits of continuous renal replacement therapy over intermittent blood purification.
CRRT - Market by Segments
Also, acute renal failure patients can effectively be treated with CVVHD. The main driver of the market's growth is the fact that continuous venovenous hemodialysis treatment is ideal for the elderly population worldwide and has several technological benefits.
Baxter International Inc. (US), Fresenius Medical Care AG & Co. KGaA (Germany), NIKKISO CO., LTD. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), Toray Medical Co., Ltd. (Japan), Infomed SA (Switzerland), Medtronic plc (Ireland), Medica S.p.A. (Italy) are some the major key players in the Continuous Renal Replacement Therapy Market.
The increase in the prevalence of sepsis, acute kidney injury (AKI), and the implementation of several important tactics by major industry participants are driving the market for continuous renal replacement therapy. The primary driver of the market's expansion is the rise in demand for continuous renal replacement treatment on a global scale. As an illustration, the International Society of Nephrology (INR) estimates that 13.3 million people would have experienced acute kidney damage worldwide in 2020. Also, the market is growing as a result of an increase in the frequency of kidney-related disorders and the world's aging population. The market is expanding because of the development of technologically sophisticated paediatric CRRT solutions.